Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Background & Objectives: Proton Pump Inhibitors (PPIs) are among the most prescribed medications in Turkey. The use of proton
pump inhibitors is one of the risk factors associated with treatment failure or unresponsiveness for clopidogrel therapy. Our objective
is to describe the prescribing patterns of proton pump inhibitors among the cardiovascular patient in Turkish population.
Methodology & Setting: A retrospective study was conducted in 100 patients� prescriptions that contain clopidogrel were collected
in a period of 3 months from three community pharmacies. Demographic variables were collected from the pharmacy online system
and indications for both proton pump inhibitor and clopidrogel were identified. Patterns of drug prescriptions were evaluated and the
change in prescription with time was also taken into account.
Main outcome measures: The use of PPI like lansoprazol, esomeprazol, pantoprazole, omeprazole, rabeprazole, and clopidogrel
were evaluated by using pharmacy medication record system within 6 months period. Prescriptions that include PPI and clopidogrel
simultaneously were highlighted. Drug-drug interaction was checked using Medscape drug interaction checker.
Results: In the current study, findings showed that, 74% of patients receiving clopidogrel and PPI simultaneously where 26% of
patients had received clopidogrel with PPI in the same prescription. The prescription patterns of PPI were found as 25%, 13%, 28%,
and 8% for lansoprazole, esomeprazole, pantoprazole and rabeprazole, respectively. Significant drug-drug interaction between PPI
and clopidogrel was detected in 38% of patients, 31.7% of these patients received both drugs at the same prescription. 22.9% of the
patients had different PPI in the medication histories, 16% of these changes were incorrectly and 6.9% were correctly done.
Conclusion: Although most of the prescriptions contain pantoprazole or rabeprazole, there are still some prescriptions that contain
lansoprazole in combination with clopidogrel, may reduce the effectiveness of clopidogrel in preventing heart attack or stroke.
Community pharmacist must be aware of these types of interaction and must play a role in preventing and monitoring them by
calling the prescribers if possible. Increasing the community pharmacist�s knowledge towards these types of interactions will lead to
decrease the negative economic and health impacts of drug interactions.